← Back to Clinical Trials
Recruiting Phase 2 NCT07150845
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
Trial Parameters
Condition Atoptic Dermatitis
Sponsor Evommune, Inc.
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 120
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-08-26
Completion 2026-07
Interventions
EVO756EVO756EVO756
Brief Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Eligibility Criteria
Inclusion Criteria: * Chronic AD that has been present for ≥6 months * Validated-Investigator's Global Assessment score of ≥3 * EASI of ≥16 * BSA of AD involvement of ≥10% Exclusion Criteria: * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening * Use of certain medications * Presence of skin comorbidities or other condition(s) that may interfere with study assessments * Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry